학술논문

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Document Type
Article
Source
In Blood 22 February 2024 143(8):673-684
Subject
Clinical Trials and Observations
Immunobiology and Immunotherapy
Lymphoid Neoplasia
Language
ISSN
0006-4971